Findings showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission, clinical response, and endoscopic improvement compared with placebo.
Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep ...
100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study TORONTO, Sept. 19, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback